An oral combination treatment may prevent the progression of advanced leiomyosarcoma, one of the most common subtypes of soft ...
Cabozantinib plus temozolomide led to favorable short-term progression-free survival in a single-arm trial of patients with advanced leiomyosarcoma. The combination of cabozantinib with temozolomide ...
When surgery is part of the treatment plan, choosing a team with deep sarcoma-specific surgical experience is one of the most important decisions a patient can make. With more than 70 distinct sarcoma ...
Success rates for drug development in solid tumors remain the lowest of the many therapeutics areas in medicine. Recent advances in drug discovery and development have transformed available therapies ...
Sarcoma originates in connective tissues, with soft tissue and bone sarcomas as primary categories, each having multiple subtypes. Staging considers tumor size, grade, and metastasis, guiding ...
WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading AI-based molecular and immune profiling solutions provider, and the Sarcoma Oncology Center, announced a collaboration to expedite the ...
An expert writes about his experience as a sarcoma medical oncologist and how the field may progress with several therapies in the pipeline. As a sarcoma medical oncologist, the No. 1 question I am ...
Updated NCCN pediatric STS guidelines emphasize risk stratification, imaging, multimodal therapy, and clinical trial enrollment to improve outcomes. The National Comprehensive Cancer Network (NCCN) ...
Uterine leiomyosarcoma is a rare form of cancer. The earlier uterine leiomyosarcoma is diagnosed, the better the outlook. Uterine leiomyosarcoma accounts for 2–5% of all uterine cancers. It starts in ...
If you would like a patient care coordinator to reach out to you, please fill out our form to schedule an information call. Form: Schedule a Call with a Patient Care Coordinator Proton therapy is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results